Argonne X-rays used to help identify a key Lassa virus structure
(DOE/Argonne National Laboratory) Research done at Argonne National Laboratory's Advanced Photon Source was vital to the process of identifying the structure, which provides a guide for designing a Lassa virus vaccine. Lassa virus is endemic to Africa and kills thousands of people a year; it is particularly deadly for pregnant women.
ConclusionThough conclusions must be drawn with caution this research presents a number of potential implications, the main one being a proposed policy recommendation for women to take folic acid for the duration of pregnancy rather than stopping at the end of the first trimester. The second is the potential for future research to explore the possible psychological and social development benefits and in line with this to try and identify the explanatory mechanism involved.This article is protected by copyright. All rights reserved.
New treatments for hepatitis C virus (HCV) infection with direct-acting antivirals provide an extraordinary cure rate. A recent Article by Xavier Forns and colleagues1 shows an outstanding 99% sustained virological response among all viral genotypes. Because HCV infection is now a curable disease, attention should be focused towards HCV-related complications and indirect effects. Multiple studies in the past have shown that individuals infected with HCV mount a poor response to vaccination against hepatitis B virus (HBV).
On Jan 3, 2018, WHO announced the prequalification of a typhoid conjugate vaccine (TCV) manufactured by the Indian firm Bharat Biotech. The decision was expected after last year's endorsement by WHO's Strategic Advisory Group of Experts (SAGE) on immunisation, which recommended that the TCV be introduced for infants and children older than 6 months in typhoid-endemic countries.
Conclusions: Our data demonstrate that a significant number of children lose preexisting humoral immunity against MMR and hepatitis B after completion of chemotherapy.
An experimental oral rotavirus vaccine, when given at birth and in two subsequent doses, can reduce the rate of severe and potentially deadly diarrhea by 75%, according to new study conducted among Indonesian babies.Reuters Health Information
After a two-year hiatus, the nasal flu vaccine is set to return to doctors’ offices next year. The Advisory Committee on Immunization Practices (ACIP) voted 12 to 2 on Wednesday to return the nasal spray to the CDC’s list of recommended vaccines for the 2018-2019 flu season. Pending final approval from the CDC director, the vote would greenlight the spray for widespread use and compel insurance companies to cover it. The committee stopped short of explicitly recommending the nasal spray, however, and will instead let providers and patients decide if they’ll use it instead of traditional flu shots. There ...
FluMist, the inhaled flu vaccine, may be on its way back to doctors’ offices in the U.S. A CDC vaccine committee voted Wednesday to put the nasal spray back on its list of available vaccines.
FluMist Quadrivalent has returned to the Centers for Disease Control and Prevention's recommended list of flu vaccines, drugmaker AstraZeneca announced.
If you avoided getting a flu vaccine this year because you're needle-phobic, there's good news: the nasal spray is coming back. The U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices voted 12 to 2 Wednesday to allow FluMist, the only non-injected flu vaccine approved for use in the United States, to return to the disease prevention arsenal for the 2018-2019 flu season after a two-year suspension. The nasal spray had been shelved as an option after…